BrightPath Biotherapeutics is a company that specializes in cancer immunotherapy. It develops a cancer peptide vaccine GRN-1201, immunomodulatory antibodies, and other products. In addition, the company focuses on induced pluripotent stem cell (iPSC)-derived regenerated natural killer T-cells (NKT) therapy.